



## PROVISIONAL HTA TOPIC PRIORITIZATION LIST 2024 - CYCLE 2 TOPICS FOR STAKEHOLDER CONSULTATION

Published as of 12 April 2024 (Friday)

Following the HTA Topic Nomination period from 02 October (Monday) to 17 November 2023 (Friday), the subsequent scoring of eligible nominated topics for prioritization based on the HTA Topic Prioritization Tool (refer to the [2023 Topic Nomination and Prioritization Guidelines](#) for more details) and careful deliberation, the HTA Council hereby makes public the provisional HTA Topic Prioritization List 2024 - Cycle 2 Topics for stakeholder consultation from 12 to 26 April 2024 (Friday). Kindly see the list below:

Health Technology		Indication
1	Abacavir + Lamivudine 120mg/ 60mg dispersible tablet	Human immunodeficiency virus (HIV) in pediatric population
2	Alectinib 150mg capsule	Anaplastic lymphoma kinase-positive locally advanced/metastatic Non-Small Cell Lung Cancer (NSCLC)
3	Budesonide + Glycopyrronium + Formoterol 160 mcg/7.2 mcg /4.8 mcg per actuation, pressurized metered dose suspension for inhalation	Chronic obstructive pulmonary disease (COPD) which is not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta agonist (LABA) or combination of a LABA and a long-acting muscarinic antagonist (LAMA)
4	Chip-based RT-PCR MTB test (TrueNat)	Drug-susceptible tuberculosis (DS-TB)
5	Chip-based RT-PCR MTB- RIF test (TrueNat MTB Plus, TrueNat MTB-RIF)	Rifampicin-resistant tuberculosis (RR-TB)/ Multi-drug resistant tuberculosis (MDR-TB)
6	Cinacalcet (as hydrochloride) 30mg film-coated tablet	Secondary hyperparathyroidism in patients with chronic kidney disease (CKD)
7	Dapivirine Vaginal Ring 25 mg vaginal delivery system	HIV pre-exposure prophylaxis (PrEP)
8	Dexmedetomidine (as hydrochloride) - 100 mcg/ mL (200 mcg/ 2mL) Concentrate for Intravenous Infusion, 2mL glass vial - 4 mcg/mL in 0.9% w/v Sodium Chloride Solution for intravenous infusion (premixed), 50 mL glass bottle	Intensive Care Unit (ICU) sedation, procedural sedation
9	Dibenzozide 1 mg capsule	Premature neonates and low birth weight neonates
10	Donepezil hydrochloride 23 mg film-coated tablet	Moderate to severe Alzheimer's Disease
11	Durvalumab	Locally advanced NSCLC

	<ul style="list-style-type: none"> <li>- 120mg/ 2.4mL (50mg/mL), 10 mL vial concentrate for solution for IV infusion</li> <li>- 500mg/ 10mL (50mg/mL), 10 mL vial concentrate for solution for IV infusion</li> </ul>	
12	<p>Edoxaban</p> <ul style="list-style-type: none"> <li>- 30 mg film-coated tablet</li> <li>- 60 mg film-coated tablet</li> </ul>	Acute Ischemic Stroke in adults with nonvalvular atrial fibrillation
13	<p>Eribulin</p> <p>500 mcg/mL (1mg/ 2mL), 5 mL vial solution for injection (IV)</p>	Metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer
14	<p>Eribulin</p> <p>500 mcg/mL (1mg /2mL), 5 mL vial solution for injection (IV)</p>	Metastatic triple negative breast cancer
15	<p>Exemestane</p> <p>25 mg tablet</p>	Hormone-receptor positive advanced breast cancer (ABC) in women with natural or induced postmenopausal status
16	<p>Factor VIII Inhibitor Bypassing Activity</p> <ul style="list-style-type: none"> <li>- 500U/10mL powder solution for infusion (IV)</li> <li>- 1000U/20mL powder solution for infusion (IV)</li> <li>- 2500U/50mL powder solution for infusion (IV)</li> </ul>	Hemophilia B with inhibitors
17	<p>Factor VIII Inhibitor Bypassing Activity 500U/10mL powder solution for infusion (IV)</p> <ul style="list-style-type: none"> <li>- 1000U/20mL powder solution for infusion (IV)</li> <li>- 2500U/50mL powder solution for infusion (IV)</li> </ul>	Hemophilia A with inhibitors
18	<p>Fulvestrant</p> <p>250mg/ 5mL, 5mL single-dose pre-filled syringe for injection</p>	Advanced/metastatic hormone positive breast cancer
19	<p>Gadoxetic acid (Disodium)</p> <ul style="list-style-type: none"> <li>- 0.25 mmol/mL, 5mL solution for injection</li> <li>- 0.25 mmol/mL, 7.5mL solution for injection</li> <li>- 0.25 mmol/mL, 10 mL solution for injection</li> </ul>	T1-weighted magnetic resonance imaging of the liver
20	<p>Gefitinib</p> <p>250 mg film-coated tablet</p>	Locally advanced/metastatic NSCLC with activating mutations of epidermal growth factor receptor (EGFR)
21	<p>Glucose (544mL) + Amino Acids (315mL) + Electrolytes + Lipids (141mL), 1000 mL emulsion for IV infusion</p>	Disease-related malnutrition in hospitalized patients
22	<p>Hexavalent vaccine (Diphtheria, Tetanus, Acellular pertussis, Inactivated Poliomyelitis and <i>Haemophilus influenzae</i> Type B conjugate vaccine, adsorbed)</p> <p>0.5 mL suspension for injection (IM), 1mL glass pre-filled syringe</p>	Active immunization of infants and toddlers to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to <i>Haemophilus influenzae</i> type b
23	<p>High Protein (as Semi Modular Enteral Nutrition)</p> <p>400g tin can, 25g aluminum sachet &amp; 400g plastic jar</p>	Protein supplementation
24	<p>Human papillomavirus (HPV) vaccine 9-valent (types 6, 11, 16, 18, 31, 33, 45, 52, 58)</p> <p>recombinant vaccine, 0.5mL suspension for intramuscular injection in 1.5 mL syringe</p>	HPV-related infection and cancer
25	<p>Ibuprofen</p> <ul style="list-style-type: none"> <li>- 400 mg/4mL, 6 mL vial for IV infusion</li> <li>- 800 mg/8mL, 10mL vial for IV infusion</li> </ul>	<p>Pediatric patients six months and older for the:</p> <ul style="list-style-type: none"> <li>- Management of mild to moderate pain</li> <li>- Management of moderate to severe pain as an adjunct to opioid</li> </ul>

		analgesics
26	Icodextrin (Extraneal 7.5%) peritoneal dialysis solution, 2L Ambuflex container (single bag); 2L Ultrabag (twin bag)	End Stage Renal Disease (ESRD) requiring home dialysis
27	Inclisiran 284 mg/ 1.5 mL solution for injection (SC), 2.25 mL prefilled syringe	Hypercholesterolemia/ dyslipidemia among adults with previous cardiovascular event
28	Inclisiran 284 mg/ 1.5 mL solution for injection (SC), 2.25 mL prefilled syringe	Hypercholesterolemia/ dyslipidemia among adults with Type 2 Diabetes Mellitus who have not had a cardiovascular event
29	Insulin glargine 300 units/mL (equivalent to 10.91 mg/mL) solution for Injection, 1.5 mL prefilled syringe	Type 1 Diabetes Mellitus
30	Insulin glargine 300 units/mL (equivalent to 10.91 mg/mL) solution for injection, 1.5 mL prefilled syringe	Type 2 Diabetes Mellitus
31	Insulin glargine + Lixisenatide - 3.64 mg (equivalent to 100 Units of insulin glargine)/ 33 mcg per mL solution for injection, 3 mL cartridge - 3.64 mg (equivalent to 100 Units of insulin glargine)/ 50 mcg per mL solution for injection, 3 mL cartridge	Type 2 Diabetes Mellitus
32	Interferon gamma release ELISA assay (IGRA) ( <i>QuantiFERON-TB Gold Plus [QFT-Plus]</i> )	Detection of latent/ asymptomatic tuberculosis
33	Irbesartan + Amlodipine - 150mg/ 5mg film-coated tablet - 300mg/ 5mg film-coated tablet - 300mg/ 10mg film-coated tablet	Essential hypertension
34	Lateral flow uterine lipoarabinomannan assay (LF-LAM)	Active mycobacterial infection in HIV patients
35	Levonorgestrel 75mg Subdermal implant	Contraception
36	Levonorgestrel (52mg) Intrauterine Device (IUD)	Contraception
37	Line Probe Assay ( <i>GenoType MTBDR-Plus</i> )	RR-TB/ MDR-TB
38	Line Probe Assay ( <i>GenoType MTBDRsl</i> )	Extensively drug-resistant ( <i>XDR</i> ) <i>Mycobacterium tuberculosis</i> complex tuberculosis
39	Lorlatinib 25 mg and 100 mg tablets	Anaplastic lymphoma kinase-positive advanced NSCLC
40	Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine 5 mcg Lyophilized Powder for Solution for Injection (IM) in clear glass vial + 0.5 mL prefilled glass syringe (0.9% Sodium Chloride as diluent) with 2 separate needles	Active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by <i>Neisseria meningitidis</i> group A, C, W-135 and Y
41	Multiple Micronutrient Supplement Capsule for Pregnant and Lactating Women	Prevention of vitamin and mineral deficiencies; improve iron status, and reduce anemia among pregnant and lactating women
42	Olaparib	Newly diagnosed advanced BRCA-mutated,

	<ul style="list-style-type: none"> <li>- 100 mg film-coated tablet</li> <li>- 150 mg film-coated tablet</li> </ul>	high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to first-line platinum-based chemotherapy
43	<p>Osimertinib</p> <ul style="list-style-type: none"> <li>- 80 mg Tablet</li> <li>- 40 mg Tablet</li> </ul>	Adjuvant treatment after tumor resection in patients with NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
44	<p>Pancreatin</p> <p>150mg capsule</p>	Pancreatic Exocrine Insufficiency (PEI)
45	<p>Parecoxib</p> <p>40 mg Lyophilized Powder for IM/IV Injection</p>	Short-term treatment of acute pain and post-operative pain
46	<p>Pertuzumab</p> <p>30 mg/mL (420 mg/14 mL) concentrate for solution for infusion, 14mL single-use vial</p>	HER2-positive metastatic or locally recurrent unresectable breast cancer
47	<p>Pertuzumab + Trastuzumab</p> <ul style="list-style-type: none"> <li>- 1200 mg + 600 mg per 15 mL, 20 mL vial solution for injection (SC)</li> <li>- 600 mg + 600 mg/10 mL, 15 mL vial solution for injection (SC)</li> </ul>	Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early breast cancer
48	<p>Polatuzumab</p> <p>140 mg powder concentrate for solution for infusion (IV)</p>	Treatment of adult patients with diffuse large B-cell lymphoma who have received at least one prior therapy
49	<p>Rosuvastatin (as calcium) + Ezetimibe</p> <ul style="list-style-type: none"> <li>- 10mg/ 10mg film-coated Tablet</li> <li>- 20mg/ 10mg film-coated Tablet</li> </ul>	Reduction of risk of cardiovascular events in patients with coronary heart diseases (CHD) and a history of acute coronary syndrome (ACS)
50	<p>RT- PCR MDR-TB Assay</p> <p>(BD MAX MDR-TB Assay)</p>	RR-TB/MDR-TB
51	<p>RT-PCR MTB/RIF Ultra Assay</p> <p>(Cepheid Xpert)</p>	RR-TB/MDR-TB
52	<p>RT-PCR MTB/XDR Assay</p> <p>(Cepheid Xpert)</p>	XDR <i>M. tuberculosis</i> complex tuberculosis
53	<p>Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate</p> <p>1.544 g/83.16 mg/ 63.13 powder for reconstitution</p>	Sinusitis
54	<p>Somatropin</p> <ul style="list-style-type: none"> <li>- 5.3mg/mL Powder and Solvent for Solution for Injection (SC)</li> <li>- 12mg/mL Powder and Solvent for Solution for Injection (SC)</li> </ul>	Growth disturbance due to insufficient secretion of growth hormone among pediatric patients
55	<p>Tenofovir + Lamivudine + Dolutegravir (TLD)</p> <p>300mg / 300 mg / 50 mg tablet</p>	HIV treatment for treatment-experienced people living with HIV (PLHIV) (including those that are stable in their current regimen)
56	<p>Tenofovir + Lamivudine</p> <p>300mg / 300mg tablet</p> <p><i>In combination with</i></p>	HIV treatment for treatment-experienced PLHIV (including those that are stable in their current regimen)

	Dolutegravir 50 mg tablet	
57	Zinc Oxide + Calamine 555.7 mg/ 164.5 mg, per 3.5 g Topical Ointment	Incontinence-induced dermatitis
58	Zinc Oxide + Calamine 555.7 mg/ 164.5 mg, per 3.5 g Topical Ointment	Diaper dermatitis

Appeals can be made based on differences in the following only:


- Disease severity
- Disease cost estimates
- Interpretation of the action of the HT on the disease

Stakeholders may submit their appeals by accomplishing and submitting the HTA *Topic Prioritization Appeals Requirements* (access link: [bit.ly/2023PrioAppealForm](https://bit.ly/2023PrioAppealForm)) to the HTA Philippines via email at [htanominations@dost.gov.ph](mailto:htanominations@dost.gov.ph) within the prescribed deadline. The requirements as specified in the access link are as follows:

Requirements		Description
1	<b>Cover Letter</b>	A letter addressed to the Chairperson of the HTA Council signifying an appeal to the shortlisted HTA priority topics
2	<b>Topic Prioritization Appeals Form</b>	The Topic Prioritization Appeals Form is composed of the following: Section 1: Appellant details and contact information Section 2: General information regarding the health technology Section 3: Summary of the justification for the appeal Section 4: References
3	<b>Attachments</b>	Copies of all references listed in the Topic Prioritization Appeals Form

**Only appeals that are based on the acceptable grounds, have complete sets of requirements, and submitted on time to the correct email address will be processed.**

Following the end of stakeholder consultation on 26 April 2024 (Friday), the aim is to release the list of final prioritized topics by the fourth week of May 2024 and the assessments are aimed to commence within the third quarter of 2024. Thank you very much and best regards.



**ANNE JULIENNE GENUINO-MARFORI, RPh, MSc**  
Division Chief  
HTA Division



**MARITA V. TOLENTINO-REYES, MD**  
Chairperson  
HTA Council